Analyst Viewpoint
Rapid increase in geriatric population and rise in awareness about Parkinson's disease and anticipated launch of emerging therapies are driving the Parkinson's disease therapeutics market growth. Moreover, increase in access and availability of several supportive therapies and medications for Parkinson’s treatment is estimated to propel market development in the next few years.
Growing investment in research and development coupled with rising spending on healthcare by governments across the globe is bolstering the development of novel therapeutic approaches for Parkinson's. Furthermore, increase in availability of diagnostic laboratories is fueling the number of patient visits to hospitals for the diagnosis of Parkinson’s disease. This, in turn, is estimated to positively influence the Parkinson's disease therapeutics market forecast in the next few years.
Parkinson’s disease is a progressive brain disorder that is caused due to the degeneration of nerve cells in the part of the brain that controls movement. The precise cause of degeneration of nerve cells is unknown; however, exposure to environmental risk factors and genetics are suspected to be probable causes.
Common symptoms of Parkinson's include issues with balance and coordination, memory difficulties, sleep problems, depression, and stiffness. Currently, there is no X-ray or blood test that can confirm the condition; the disease is diagnosed mostly based on the symptoms listed above. Noninvasive diagnostic imaging, such as positron emission tomography (PET) scan, can help a doctor make a diagnosis.
Among the key strategies for Parkinson's control are accurate diagnosis, and pharmacologic treatments. Different types of medications are available; however, they cannot reverse Parkinson's disease. Medications are prescribed to manage symptoms and movement issues in patients.
According to Parkinson's Foundation, the combined direct and indirect cost of Parkinson’s, including treatment, social security payments and lost income, is estimated to be nearly $52 billion per year in the U.S. EUR 68 Bn in Europe, and GBP 40 Bn in the U.K. These costs include hospitalizations, medication, rehabilitation, and other services related to diagnosis and management of disease.
These figures are more than double the previous estimates and are indicative of the growing impact of Parkinson’s disease on individuals, families, employers, and society. Therefore, high cost associated with Parkinson's management, reimbursement issues, and shortage of healthcare specialists are estimated to hamper the Parkinson's disease therapeutics industry growth during the forecast period.
Prevalence of a disease is the number of people who have the disease at a given time. It can vary according to age, gender, region, and diagnostic criteria of the population. According to Parkinson's Foundation, nearly one million people in the U.S. are living with Parkinson's disease. This number is expected to rise to 1.2 million by 2030. This is projected to offer lucrative Parkinson's disease therapeutics market opportunities for drug manufacturers across the globe
Parkinson's is the second-most common neurodegenerative disease after Alzheimer's disease. More than 10 million people, worldwide, are living with Parkinson's disease. The risk increases with age, but an estimated four percent of people with Parkinson's are diagnosed before the age 50. Men are 1.5 times more likely to have Parkinson's disease than women.
More than 10 million people in Europe have Parkinson's. The prevalence rate ranges from 41 people per 100,000. In the U.K., around half a million people are living with Parkinson's disease and the prevalence rate was estimated to be around 40 per 100,000 in 2018.
An individual with Parkinson's disease takes a combination of medications, different doses at different times of the day, to manage symptoms. Parkinson's disease treatment is offered based on the stage of the disease, the symptoms displayed, and those who are already on medicine.
Leading drug manufacturers are focusing on development of drugs that can improve or reduce the symptoms of Parkinson’s by regulating the levels of dopamine or boosting its signaling in the brain. Several pharma players are undertaking clinical trials to test new agents that can target the underlying causes of Parkinson's disease.
In September 2023, FAScinate Therapeutics Inc. announced a study of phase 2 clinical trials for KM-819. The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. Furthermore, in May 2022, AbbCie Inc. submitted a New Drug Application (NDA) to the US FDA for ABBV-951 (foscarbidopa/foslevodopa) to treat motor fluctuations in patients suffering from advanced PD.
Growing demand for effective therapies and medications with novel mechanisms of action and combinations to treat Parkinson's is estimated to propel the global Parkinson's disease therapeutics market in the next few years
Increase in prevalence of Parkinson’s illness in Europe, surge in initiatives by government organizations for the treatment of Parkinson’s disorders, and the strong drug pipeline of drug makers based in the region contributed to the prominent Parkinson's disease therapeutics market share held by Europe in 2022. The region is estimated to maintain its strong position in the global market during the forecast period owing to the growing number of drug approvals by regulatory authorities in Europe.
According to the latest global Parkinson's disease therapeutics market analysis, North America accounted for a notable share of global demand for Parkinson’s therapeutics. Growing incidence of Parkinson’s in the U.S., increase in spending on R&D in healthcare, and rise in preference for non-pharmaceutical approaches to Parkinson's treatment are expected to fuel the Parkinson’s disease therapeutics industry size in North America in the near future.
The global Parkinson’s disease therapeutics business is highly fragmented with the presence of several global players. Leading players are following the latest market trends and focusing on the development of new therapies. They are also conducting clinical trials to introduce novel drugs and consolidate their presence in the global market. A few prominent players operating in the global market are AbbVie, Inc., UCB Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Novartis AG, Boehringer Ingelhelm GmbH, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., and STADA Arzneimittel AG.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 5.1 Bn |
| Forecast (Value) in 2031 | US$ 9.2 Bn |
| Growth Rate (CAGR) | 7.0% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 5.1 Bn in 2022
It is projected to expand at a CAGR of 7% from 2023 to 2031
Growing prevalence of Parkinson’s disease and strong pipeline drugs
In terms of distribution channel, the hospital pharmacy segment held largest share in 2022
Europe is estimated to dominate in the next few years
AbbVie, Inc., UCB Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Novartis AG, Boehringer Ingelhelm GmbH, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., and STADA Arzneimittel AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Parkinson’s Disease Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Levodopa Combination
6.3.2. Dopamine Agonists
6.3.3. MAO-B Inhibitors
6.3.4. COMT Inhibitors
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Transdermal
7.3.3. Subcutaneous
7.3.4. Intestinal Infusion
7.3.5. Others
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Levodopa Combination
10.3.2. Dopamine Agonists
10.3.3. MAO-B Inhibitors
10.3.4. COMT Inhibitors
10.3.5. Others
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Transdermal
10.4.3. Subcutaneous
10.4.4. Intestinal Infusion
10.4.5. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Levodopa Combination
11.3.2. Dopamine Agonists
11.3.3. MAO-B Inhibitors
11.3.4. COMT Inhibitors
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Transdermal
11.4.3. Subcutaneous
11.4.4. Intestinal Infusion
11.4.5. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Levodopa Combination
12.3.2. Dopamine Agonists
12.3.3. MAO-B Inhibitors
12.3.4. COMT Inhibitors
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Transdermal
12.4.3. Subcutaneous
12.4.4. Intestinal Infusion
12.4.5. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Levodopa Combination
13.3.2. Dopamine Agonists
13.3.3. MAO-B Inhibitors
13.3.4. COMT Inhibitors
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Transdermal
13.4.3. Subcutaneous
13.4.4. Intestinal Infusion
13.4.5. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Levodopa Combination
14.3.2. Dopamine Agonists
14.3.3. MAO-B Inhibitors
14.3.4. COMT Inhibitors
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Transdermal
14.4.3. Subcutaneous
14.4.4. Intestinal Infusion
14.4.5. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AbbVie, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. UCB Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Valeant Pharmaceuticals International, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Boehringer Ingelhelm GmbH
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. GlaxoSmithKline Plc
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. STADA Arzneimittel AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 08: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 12: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 24: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Parkinson’s Disease Therapeutics Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Parkinson’s Disease Therapeutics Market Value Share, by Drug Class, 2022
Figure 04: Global Parkinson’s Disease Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Parkinson’s Disease Therapeutics Market Value Share, by Route of Administration, 2022
Figure 06: Global Parkinson’s Disease Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Parkinson’s Disease Therapeutics Market Value Share, by Distribution Channel, 2022
Figure 08: Global Parkinson’s Disease Therapeutics Market Value Share, by Region, 2022
Figure 09: Global Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 11: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 12: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 13: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 14: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 16: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 22: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 23: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 25: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 26: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 32: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 35: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 40: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 41: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 44: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 50: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 52: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 53: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 58: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 59: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 62: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Parkinson’s Disease Therapeutics Market
